Abstract:Suxing Liu, 1 Di Li, 1 Jian Liu, 2 Huiyun Wang, 1 Ivana Horecny, 1 Ru Shen, 1 Rumin Zhang, 1 Heping Wu, 2 Qiyue Hu, 3 Peng Zhao, 2 Fengqi Zhang, 2 Yinfa Yan, 2 Jun Feng, 4 Linghang Zhuang, 2 Jing Li, 1 Lianshan Zhang, 5 Weikang Tao 5 1 Department of Biology, Eternity Bioscience Inc., Cranbury, NJ, 08512, USA; 2 Department of Chemistry, Eternity Bioscience Inc., Cranbury, NJ, 08512, USA; 3 Department of Molecular Modeling, Shanghai Hengrui Pharmaceutical Co. Ltd., Shanghai, 200245, People's Republic of China; 4 Department of Process Chemistry, Shanghai Hengrui Pharmaceutical Co. Ltd., Shanghai, 200245, People's Republic of China; 5 R&D Center, Shanghai Hengrui Pharmaceutical Co. Ltd., Shanghai, 200245, People's Republic of China Correspondence: Suxing Liu Department of Biology, Eternity Bioscience Inc, 6 Cedarbrook Drive, Cranbury, NJ, 08512, USA Email Introduction: CD73 and adenosine support growth-promoting neovascularization, metastasis, and survival in cells, and promote anti-PD-1 mAb therapy-induced immune escape. Consequently, developing a CD73 inhibitor as monotherapy and a potential beneficial combination partner with immune-checkpoint inhibitors needs investigation. Methods: CD73 inhibitors were evaluated in vitro with soluble and membrane-bound CD73 enzymes, as well as its PD biomarker responses in human peripheral blood mononuclear cells (PBMC) by flow cytometry and ELISA. The binding modes of the molecules were analyzed via molecular modeling. The anti-tumor activity and synergistic effect of SHR170008 in combination with anti-PD-1 mAb were evaluated in a syngeneic mouse breast cancer model. Results: SHR170008 was discovered during the initial structural modifications on the link between the ribose and the α-phosphate of AMPCP, which significantly improved the stability of the compound confirmed by the metabolite identification study. Further modifications on the adenine base of AMPCP improved the potency due to forming stronger interactions with CD73 protein. It exhibited potent inhibitory activities on soluble and endogenous membrane-bound CD73 enzymes, and induced IFNγ production, reversed AMP-suppressed CD25 + and CD8 + /CD25 + expression, and enhanced granzyme B production on CD8 + T cells in human PBMC. SHR170008 showed dose-dependent anti-tumor efficacy with suppression of adenosine in the tumors in EMT6 mouse breast tumor model. The increase of adenosine in tumor tissue by anti-PD-1 mAb alone was suppressed by SHR170008 in the combination groups. Simultaneous inhibition of CD73 and PD-1 neutralization synergistically enhanced antitumor immunity and biomarkers in response, and exposures of SHR170008 were correlated with the efficacy readouts. Conclusion: Our findings suggest that CD73 may serve as an immune checkpoint by generating adenosine, which suppresses the antitumor activity of anti-PD-1 mAb, and inhibition of CD73 may be a potential beneficial combination partner with immune-checkpoint inhibitors to improve their therapeutic outcomes in general. Keywords: small-molecule inhibitor of CD73, adenosine, anti-PD-1 mAb, checkpoint blockade, immunotherapy, combination therapy Here we described SHR170008, a novel and potent small-molecule inhibitor of CD73. An outstanding feature of SHR170008 different from AMPCP is that the bisphosphonic acid was replaced by methylenephosphonic acid, which significantly improved the stability of the compound confirmed by the metabolite identification study. Furthermore, SHR170008 not only could rescue the inhibitory effect of adenosine derived from AMP in the activation and proliferation of CD8 + T cells and granzyme B production in human primary immune cells but also exhibited dose-dependent tumor growth inhibition in single agent and significantly enhanced the efficacy in combination with anti-PD-1 mAb in EMT6 mouse breast tumor model. PD-1 blockade resulted in enhanced adenosine levels in tumor as compared with the control group and decreased adenosine levels in combination with SHR170008. Our findings extended the understanding of adenosine generated by CD73 in suppressing antitumor immunity, which contributed to the resistance of PD-1 checkpoint inhibition. Results from further clinical evaluation of this specific mechanism for immunotherapy of cancer, especially in combination with monoclonal antibody therapies targeting immune checkpoints are highly anticipated. T cell-mediated anti-tumor immune responses are pivotal for effective ablation of primary tumor lesions and for protection aga -Abstract Truncated-

Discovery of Novel Non-Nucleoside Inhibitors Interacting with Dizinc Ions of CD73

Correction to "Discovery of Novel Non-Nucleoside Inhibitors Interacting with Dizinc Ions of CD73"

Design, synthesis and structure-activity relationship of malonic acid non-nucleoside derivatives as potent CD73 inhibitors

Advances in CD73 inhibitors for immunotherapy: Antibodies, synthetic small molecule compounds, and natural compounds

Discovery of Novel 5-(Pyridazin-3-yl)pyrimidine-2,4(1 H,3 H)-dione Derivatives as Potent and Orally Bioavailable Inhibitors Targeting Ecto-5'-nucleotidase

A Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast Cancer

Identification of Novel CD39 Inhibitors Based on Virtual Screening and Enzymatic Assays.

Abstract LB166: Discovery of CT3021, a novel potent adenosine A2a/A2b/A1 receptor triple antagonist

Discovery of Novel Isoquinoline Analogues as Dual Tubulin Polymerization/V-ATPase Inhibitors with Immunogenic Cell Death Induction

Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist

Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum IV Complexes as Potent Antitumor Agents

Abstract 734: Inhibition of equilibrative nucleoside transporter 1 relieves intracellular adenosine-mediated immune suppression

Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A

Discovery of Pyridinone Derivatives As Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Discovery of Novel Benzo[4,5]imidazo[1,2- a ]pyrazin-1-amine-3-amide-one Derivatives as Anticancer Human A 2A Adenosine Receptor Antagonists

Discovery of Novel Non-nucleoside DOT1L R231Q Inhibitors with Improved Pharmacokinetic Properties and Anti-lung Cancer Efficacy

Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies

Identification of Phelligridin-Based Compounds as Novel Human CD73 Inhibitors

CD39/CD73/A2AR pathway and cancer immunotherapy

Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate

Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual Immunotherapy